Title

Bioavailability Study Comparing 10 mg Amlodipine Besylate Orally Disintegrating Tablets (ODT) And 10 mg Amlodipine Besylate Capsules
Phase 1, Open-Label, Randomized, Single-Dose, 2-Treatment, 2-Period Crossover Bioavailability Study Comparing 10 Mg Amlodipine Besylate Orally Disintegrating Tablets, Manufactured By Aurobindo Pharma Ltd., India To 10 Mg Amlodipine Besylate Capsules, Manufactured By Pfizer France Under Fasted Conditions
  • Phase

    Phase 1
  • Study Type

    Interventional
  • Intervention/Treatment

    amlodipine ...
  • Study Participants

    14
This study is being performed to determine the bioavailability, or extent of absorption into the body, of a 10 mg amlodipine besylate orally disintegrating tablet (ODT) as compared to the bioavailability of a 10 mg amlodipine besylate capsule.
Study Started
Mar 31
2010
Primary Completion
Jun 30
2010
Study Completion
Jun 30
2010
Results Posted
Aug 30
2011
Estimate
Last Update
Jan 28
2021

Drug Amlodipine - reference

Amlodipine capsule, 10 mg, single dose, with water

Drug Amlodipine ODT - test

Amlodipine orally disintegrating tablet (ODT), 10 mg, single dose, without water

treatment A - reference w/ water Active Comparator

Treatment B - ODT (test) w/o water Experimental

Criteria

Inclusion Criteria:

Healthy male and/or female literate subjects (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ECG and clinical laboratory tests).
Body Mass Index (BMI) of 17.5 to 26.4 kg/m2; and a total body weight >50 kg (110 lbs).

Exclusion Criteria:

Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
A positive urine drug screen.

Summary

Amlodipine 10 mg Capsule

Amlodipine 10 mg ODT

All Events

Event Type Organ System Event Term

Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-∞)]

AUC (0-∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-∞). It is obtained from AUC (0-t) plus AUC (t-∞).

Amlodipine 10 mg Capsule

401.655
hr*ng/mL (Geometric Mean)
Full Range: 61.74 to 566.54

Amlodipine 10 mg ODT

360.619
hr*ng/mL (Geometric Mean)
Full Range: 266.76 to 635.54

Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)

Area under the plasma concentration-time curve from time zero (pre-dose) to the time of the last measurable concentration (AUClast).

Amlodipine 10 mg Capsule

331.3
hr*ng/mL (Geometric Mean)
Full Range: 60.42 to 463.69

Amlodipine 10 mg ODT

330.394
hr*ng/mL (Geometric Mean)
Full Range: 243.87 to 558.6

Maximum Observed Plasma Concentration (Cmax)

Amlodipine 10 mg Capsule

6.427
ng/mL (Geometric Mean)
Full Range: 1.88 to 8.32

Amlodipine 10 mg ODT

5.571
ng/mL (Geometric Mean)
Full Range: 3.92 to 7.84

Time to Reach Maximum Observed Plasma Concentration (Tmax)

Amlodipine 10 mg Capsule

8.0
hr (Median)
Full Range: 6.0 to 14.0

Amlodipine 10 mg ODT

10.0
hr (Median)
Full Range: 6.0 to 14.0

Plasma Decay Half-life (t1/2)

Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.

Amlodipine 10 mg Capsule

51.374
hr (Mean)
Standard Deviation: 12.912

Amlodipine 10 mg ODT

45.12
hr (Mean)
Standard Deviation: 4.921

Age, Continuous

25.00
years (Mean)
Standard Deviation: 6.36

Sex: Female, Male

First Intervention Period

Amlodipine Capsule Then Amlodipine ODT

Amlodipine ODT Then Amlodipine Capsule

Washout Period (of 14 Days)

Amlodipine Capsule Then Amlodipine ODT

Amlodipine ODT Then Amlodipine Capsule

Second Intervention Period

Amlodipine Capsule Then Amlodipine ODT

Amlodipine ODT Then Amlodipine Capsule

Drop/Withdrawal Reasons

Amlodipine ODT Then Amlodipine Capsule